“In recent years, cannabinoid (CB) products have gained popularity among the public. The anti-inflammatory properties of CBs have piqued the interest of researchers and clinicians because they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refractory to conventional therapy.

The objective of this study was to review the existing literature regarding CBs for dermatologic conditions.

There were 13 articles on systemic CBs and 14 reports on topical CBs. Selective CB receptor type 2 agonists were found to be effective in treating diffuse cutaneous systemic sclerosis and dermatomyositis. Dronabinol showed efficacy for trichotillomania. Sublingual cannabidiol and Δ-9-tetrahydrocannabinol were successful in treating the pain associated with epidermolysis bullosa.

Available evidence suggests that CBs may be effective for the treatment of various inflammatory skin disorders. Although promising, additional research is necessary to evaluate efficacy and to determine dosing, safety, and long-term treatment guidelines.”

https://pubmed.ncbi.nlm.nih.gov/35199092/

“In conclusion, both oral and topical CBs appear to be promising therapies for the treatment of various inflammatory and autoimmune skin disorders. Despite limited studies, the compilation of current evidence from the published literature supports the utility of topical and systemic CBs for the treatment of primary inflammatory skin disorders such as DM, diffuse cutaneous systemic sclerosis, atopic dermatitis, leg ulcers, and epidermolysis bullosa.”

https://www.jidinnovations.org/article/S2667-0267(22)00001-7/fulltext